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OBJECTIVES: This pilot study investigated the safety and efficacy of a novel shunt surgery combined with foam
sclerotherapy of varices in patients with prehepatic portal hypertension.
METHODS: Twenty-seven patients who were diagnosed with prehepatic portal hypertension and underwent
shunt surgeries were divided into three groups by surgery type: shunt surgery alone (Group A), shunt surgery
and devascularization (Group B), and shunt surgery combined with foam sclerotherapy (Group C). Between-group
differences in operation time, intraoperative blood loss, portal pressure decrease, postoperative complications,
rebleeding rates, encephalopathy, mortality rates and remission of gastroesophageal varices were compared.
RESULTS: Groups A, B and C had similar operation times, intraoperative bleeding, and portal pressure decrease.
The remission rates of varices differed significantly (po0.001): one patient in Group A and 6 patients in Group B
had partial response, and all 9 patients in Group C had remission (2 complete, 7 partial). Two Group A patients
and one Group B patient developed recurrent gastrointestinal bleeding postoperatively within 12 months.
No postoperative recurrence or bleeding was observed in Group C, and no sclerotherapy-related complications
were observed.
CONCLUSIONS: Shunt surgery combined with foam sclerotherapy obliterates varices more effectively than shunt
surgery alone does, decreasing the risk of postoperative rebleeding from residual gastroesophageal varices. This
novel surgery is safe and effective with good short-term outcomes.
KEYWORDS: Prehepatic Portal Hypertension; Foam Sclerotherapy; Shunt Surgery; Gastroesophageal Varices.
’ INTRODUCTION
Prehepatic portal hypertension (PPH) is elevated pressure
of the portal vein system as a result of extrahepatic portal
venous obstruction (EHPVO) or presence of arterioportal
fistula. Stenosis, obstruction, or thrombosis of the extra-
hepatic portal vein system may result in EHPVO (1), which
is a major cause of noncirrhotic portal hypertension and
variceal bleeding in children (2,3), as well as a common
cause of upper gastrointestinal bleeding in adults (4).
The most severe and common complication of PPH is
gastrointestinal bleeding. Approximately 5% to 30% of
patients will die of gastrointestinal bleeding if timely treat-
ment is not administered (5). Thus, the goal of treatment for
PPH is to control and prevent gastrointestinal bleeding.
Vasoactive drugs (somatostatin and octreotide) can prevent
bleeding, and propranolol is used to reduce portal pressure
(6), but the effects of these drugs are limited.
Current treatments for PPH mainly include endoscopic
therapy, interventional therapy and surgery (5,7,8). Endo-
scopic sclerotherapy (EST) or band ligation are commonly
used to treat gastroesophageal varices (7). However, although
endoscopic treatment is less invasive, long-term results have
been reported to be poorer than those of other methods (9).
Endoscopic therapy does not effectively reduce portal
pressure, and bleeding typically recurs (10). Among the
interventional options for treating PPH, placement of a
transjugular intrahepatic portosystemic shunt (TIPS) is the
standard treatment for bleeding due to esophageal varices
as a result of PPH that is refractory to endoscopic therapy (11).
Surgery remains an effective strategy for the control and
prevention of PPH-related gastrointestinal bleeding (12)
and is especially applicable to patients for whom endoscopic
therapy has failed (13). Surgical interventions include various
shunt surgeries and devascularizations, and the selection is
determined by patients’ individual conditions. Portosystemic
shunts are the most common approach, including mesocaval,DOI: 10.6061/clinics/2019/e704
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splenorenal and portacaval shunts (14). Devascularization,
mainly including pericardial devascularization, esophageal
transection and the Sugiura operation, directly blocks the
paradoxical blood flow between the azygos vein and portal
vein, precisely controlling the acute bleeding of ruptured
esophageal varices and assuring blood flow to the liver (15).
However, devascularization alone cannot reduce portal vein
pressure and may result in deterioration of portal hyperten-
sive gastropathy, causing thrombosis in the portal vein and
increasing the risk of rebleeding (15). Shunt surgery and
devascularization are also used together. For example, meso-
caval shunts or splenorenal shunts can be combined with
pericardial or gastric devascularization (8). Shunt surgery
effectively reduces portal vein pressure, and devascularization
removes the varicose veins, blocks blood circulation between
the azygos vein and portal vein and maintains blood flow to
the liver, preventing variceal rebleeding and encephalopathy.
Surgeons in our hospital are still exploring surgical
approaches for PPH. Previously, we employed portosystemic
shunts such as the mesocaval shunt and proximal splenor-
enal shunt. For the past five years, we have used shunt
surgery combined with devascularization. In the last two
years, we have used shunt surgery combined with foam
sclerotherapy of the varices as an alternative method to treat
PPH, although the safety and efficacy of this operation
has not yet been reported. Therefore, this pilot study was
undertaken to compare the safety and efficacy of our novel
surgical approach with that of conventional surgeries in
obliterating esophagogastric varices and preventing post-
operative rebleeding.
’ PATIENTS AND METHODS
Patient population
In this retrospective, comparative pilot study, data from
33 patients who were diagnosed with PPH based on findings
of abdominal ultrasonography and enhanced computer tomo-
graphy (CT) between January 2007 and March 2016 were
collected. The data of 4 patients who received conserva-
tive treatment were excluded from the analysis. Of the
29 patients who received surgical interventions, 1 received
exploratory laparotomy, 1 underwent splenectomy alone,
and 27 received shunt surgery or shunt surgery combined
with other surgical interventions. Data from the 27 shunt
surgery patients were included for analysis and divided
into 3 groups according to the type of surgery received:
Group A (n=10) included patients who received shunt
surgery alone; Group B (n=8) included patients who received
shunt surgery combined with devascularization; and Group C
(n=9) included patients who received shunt surgery combined
with foam sclerotherapy.
All included patients had portal obstruction due to any
cause, resulting in increased blood flow and symptoms of
portal hypertension. Ultrasonography and CT showed filling
defects in the main portal vein, absence of a main portal vein
or portal cavernoma. The protocol for this retrospective study
was reviewed and approved by the Institutional Review
Board of Beijing Friendship Hospital. Signed consent was not
needed because the retrospective data were deidentified.
Surgical procedures
All 27 patients in the three groups underwent surgery by
the same team of surgeons. Foam sclerotherapy, for Group C
patients only, was administered during the procedure by the
surgeon after performing the shunt surgery.
Mesocaval shunt surgery. Patients received general
anesthesia, and a midline incision was made for laparotomy.
Portal pressure was measured using the piezometer before
shunting. The major superior mesenteric vein and its
branches were exposed after the mesenteric tissues were
separated and ligated. Then, the inferior vena cava was
exposed through the posterior peritoneum. The superior
mesenteric vein and inferior vena cava were clamped, and
10-15 mm incisions were made on the vessel wall. Then,
5-0 Prolene suture was used for side-to-side anastomosis.
If a side-to-side suture was impossible due to the long
distance between the superior mesenteric vein and the
inferior vena cava, an artificial (prosthetic) blood vessel
with a diameter of 8-12 mm (W.L. Gore & Associates, Newark,
DE, USA) was used to anastomose. After shunting, the pres-
sure of the omentum vein was measured again and recorded,
followed by wound closure.
Splenorenal shunt surgery. After general anesthesia,
a midline incision or an ‘‘L’’ type incision was made. Before
exploration, portal vein pressure was measured, followed
by splenectomy. Approximately 3-4 cm of the splenic
vein was reserved for further anastomosis, and the renal
vein was exposed through the posterior peritoneum. After
an incision was made on the renal vein, an end-to-side
anastomosis of the splenic and renal veins was established.
A drainage tube was placed in the splenic fossa, and the
portal vein pressure was measured again before wound
closure.
Shunt surgery combined with devascularization.
After shunt surgery, the gastric fundus was exposed, and the
proximal branches of gastroepiploic vessels and short gastric
veins were exposed along the greater and lesser curvature,
followed by ligation. Some varicose veins at the gastric body
or fundus were sutured through the gastric wall.
Shunt surgery combined with foam sclerotherapy.
After shunt surgery, the gastric varicose veins were exposed.
Foam sclerosant was made up of 2 ml of 1% polidocanol
(Aethoxysklerol, Kreussler, Wiesbaden, Germany) mixed
with 8 ml of air, as previously described by Tessari et al.
(16). Then, 2-5 ml of foam was injected into the major
varicose vein. After injection, the puncture site vessel was
ligated, followed by injection of the foam into other varicose
veins (Figure 1a, 1b). Foam sclerosant at different concentra-
tions was selected based on the size of the varicose veins;
generally, 1% foam sclerosant was used when the vessel was
smaller than 6 mm in diameter. However, if the varices
exceeded 6 mm in diameter, 3% polidocanol was applied. In
one patient with rectal varices, the inferior mesenteric vein
was exposed, and a 4 Fr sheath was inserted, followed by a
guide wire (0.035 inch) and a 4 Fr catheter inserted into the
distal inferior mesenteric vein. Contrast agent was injected to
visualize the distal inferior mesenteric vein and rectal
varices. After withdrawal of the guide wire, 3% polidocanol
foam (10 ml) was injected to occlude the rectal varices.
A second angiography showed the absence of varicose veins
(Figure 2a, 2b).
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Definitions and measures
The complete remission of gastroesophageal varices was
defined as an absence of any varicose vein in the esophagus
and gastric fundus on CT and/or gastric endoscopy; partial
remission was defined as the presence of but a reduction
in varicose veins in the esophagus and gastric fundus;
no-remission was defined as unchanged varicose veins in the
esophagus and gastric fundus. The remission rate was cal-
culated as the proportion of patients with partial remission
or complete remission to total patients.
Intraoperative and postoperative observations and
follow-up
Operation time, intraoperative blood loss, reduction in
portal pressure after shunt surgery (difference between portal
pressure before and portal pressure after shunt surgery),
incidence of postoperative complications, and mortality within
30 days after surgery were compared between groups. All
patients were examined for patency of shunts before dis-
charge. All patients had ammonia determination before being
discharged and after receiving surgery; during the postopera-
tive follow-up after discharge, patients without symptoms
of encephalopathy did not have ammonia determinations at
that time.
Patients were followed for 12 months after surgery, and
the incidence of rebleeding (hematemesis or bloody stool due
to variceal bleeding), the incidence of hepatic encephalo-
pathy and the survival rates were compared among groups
at 12 months. Findings from abdominal CT or gastric endo-
scopy before surgery and within 12 months after surgery
were also compared. The remission rates of esophageal and
gastric varices were compared after surgery among the three
groups. The possible causes of rebleeding were explored,
including the etiology (portal cavernoma or portal thrombo-
sis), reduction in portal pressure after shunt surgery and
remission of gastroesophageal varices. Associations between
these factors and rebleeding were further evaluated.
Statistical analysis
Patient characteristics are presented as n (%) for categorical
data and mean with range (min. to max.) for continuous data.
The characteristics during surgery, within 30 days and within
one year of surgery are presented as the mean ± standard
deviation (SD) for operation time, blood loss and reduction
Figure 1 - Varicose veins before and after treatment. a) Varicose veins at lesser gastric curvature. b) Occlusion of varicose veins after
injection of polidocanol foam.
Figure 2 - Rectal varices before and after treatment. a) Rectal varices on intraoperative angiography of the inferior mesenteric vein.
b) Occlusion of rectal varicose veins after injection of polidocanol foam.
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in portal pressure, and n (%) for other categorical data of
safety and efficacy evaluations. Differences among groups
were compared using the Kruskal-Wallis test for continuous
data and Fisher’s exact test for categorical data. The Mann-
Whitney U test was also applied for continuous data between
two groups. All statistical analyses were carried out using
IBM SPSS statistical software version 22 for Windows (IBM
Corp., Armonk, NY, USA).
’ RESULTS
Patient characteristics
In this retrospective pilot study, the data of 27 patients
with PPH (15 males and 12 females) with a mean age of
35.5 years (range: 8 to 62 years) were collected from January
2007 to March 2016. All patients were diagnosed via
enhanced abdominal CT screening, including 16 patients
with portal cavernoma and 11 with chronic portal venous
thrombosis. Comorbidities included 27 patients with gastro-
esophageal varices, 20 with splenomegaly, 14 with hypers-
plenism, 11 with liver cirrhosis, 10 with ascites and one with
rectal varices. The medical histories revealed that 25 patients
had gastrointestinal hemorrhage, and 2 had portal hyperten-
sive gastropathy. Eighteen patients had Child-Pugh class A
cirrhosis, and 9 had class B (Table 1).
Safety and efficacy
In Group A, a mesocaval shunt was placed in 5 patients,
a mesocaval shunt using an artificial vessel in 2 patients,
a splenectomy + splenorenal shunt in 2 patients, and a
splenocaval shunt using an artificial vessel in 1 patient.
The mean operation time was 241.0±92.0 minutes, and the
mean blood loss was 925.0±962.4 ml. The mean post-
operative reduction in portal pressure was 10.9±6.7 cm
H2O. After splenectomy, thrombocytosis was noted in one
patient who was treated with anti-platelet therapy; one
patient developed pleural and peritoneal effusion, which
was alleviated after supplementation with albumin and
diuretic treatment.
In Group B, mesocaval shunt + devascularization was
performed in 6 patients, splenectomy+ mesocaval shunt +
devascularization in 1 patient, and splenectomy+ splenorenal
shunt + devascularization in 1 patient. The mean operation
time was 246.2±31.7 minutes, and the mean intraoperative
blood loss was 475.0±315.1 ml. The mean postoperative
reduction in portal pressure was 9.2±4.6 cm H2O. After
splenectomy, one patient developed a splenic fossa abscess
and an abdominal infection, which was corrected by splenic
fossa drainage; one patient developed abdominal bleeding
within 5 hours after surgery, so a second exploratory
laparotomy was performed, and the patients had a smooth
recovery.
In Group C, mesocaval shunt + foam sclerotherapy was
performed in 8 patients, and a mesocaval shunt was placed
using an artificial vessel + foam sclerotherapy in 1 patient.
The median volume of polidocanol used in surgery was
16.9 ml. The mean operation time was 242.2±55.7 minutes,
and the mean intraoperative blood loss was 511.1±493.6 ml.
The mean reduction in portal pressure was 9.8±3.4 cm
H2O. One patient developed upper gastrointestinal bleeding
Table 1 - Patient demographics and clinical characteristics (n=27).
Total (n=27) Group A (n=10) Group B (n=8) Group C (n=9) p-value
Years n/a
2007 1 1 0 0
2008 3 3 0 0
2009 2 2 0 0
2010 4 4 0 0
2012 1 0 1 0
2013 2 0 2 0
2014 3 0 3 0
2015 8 0 2 6
2016 3 0 0 3
Sex 0.560
Males 15 (55.6) 6 (60) 3 (37.5) 6 (66.7)
Females 12 (44.4) 4 (40) 5 (62.5) 3 (33.3)
Age, years 35.5 (8-62) 29.9 (11-62) 29.4 (8-60) 47.2 (18-61) 0.108
Etiology 1.000
Portal cavernoma 16 (59.3) 6 (60) 5 (62.5) 5 (55.6)
Chronic portal vein thrombosis 11 (40.7) 4 (40) 3 (37.5) 4 (44.4)
Comorbidity
Gastroesophageal varices 27 (100) 10 (100) 8 (100) 9 (100) n/a
Splenomegaly 20 (74.1) 7 (70) 7 (87.5) 6 (66.7) 0.642
Hypersplenism 14 (51.9) 5 (50) 5 (62.5) 4 (44.4) 0.794
Liver cirrhosis 11 (40.7) 4 (40) 3 (37.5) 4 (44.4) 1.000
Ascites 10 (37) 3 (20) 5 (62.5) 2 (22.2) 0.247
Rectal varices 1 (3.7) 0 (0) 0 (0) 1 (11.1) 0.631
Medical history 0.512
Gastrointestinal hemorrhage 25 (92.6) 10 (100) 7 (87.5) 8 (88.9)
Portal hypertensive gastropathy 2 (7.4) 0 (0) 1 (12.5) 1 (11.1)
Child-Pugh class 0.098
A 18 (66.7) 7 (70) 3 (37.5) 8 (88.9)
B 9 (33.3) 3 (30) 5 (62.5) 1 (11.1)
Data are summarized as the number of patients by group for the years of patient enrollment; n (%) is shown for other categorical data; mean (range:
min.-max.) is shown for age.
n/a, not available.
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within 3 days after surgery, and endoscopy showed ulcer-
related mucosal bleeding due to the shedding of tissue glue
that was administered before surgery; this patient recovered
after blood transfusion and anti-acid treatment. One patient
developed persistent nasal bleeding due to thrombocytope-
nia, which resolved after focal hemostasis and plasma
transfusion. Sclerotherapy-related complications were not
observed in this group.
In Group A, 2 patients developed recurrent gastro-
intestinal bleeding at 4 and 10 months after surgery,
of whom 1 received endoscopic hemostasis and the other
received conservative therapy. One patient developed hepatic
encephalopathy at 5 months after surgery but recovered after
corresponding treatment, and similar symptoms were not
observed again. In Group B, recurrent bloody stool was
observed in 1 patient at 10.5 months after surgery but
resolved after conservative therapy. In the follow-up
period, obstruction of the shunt was observed in 1 patient,
but without rebleeding, and no patients developed hepatic
encephalopathy. In Group C, no postoperative rebleeding
was observed; 1 patient developed hepatic encephalopathy
at 2 months after surgery, which resolved after correspond-
ing treatment and was not observed thereafter.
Table 2 presents the operative parameters by group.
During the operations, all three groups had similar operation
times, intraoperative blood loss, and a reduction in portal
pressure (all p-values40.05) (Table 2). No patients in any
group died within 30 days after surgery. A total of 6 patients,
including 2 in Group A, 2 in Group B, and 2 in Group C,
developed complications within 30 days after surgery.
Within 12 months after surgery, a total of 3 patients had
recurrent bleeding at 4 months, 10 months, and 10.5 months;
2 patients had encephalopathy, and one experienced shunt
occlusion. The remission rates of varices were significantly
different between the three groups (po0.001): one patient
in Group A and 6 patients in Group B had partial remis-
sion; 9 patients in Group C had remission, including 2 with
complete remission (Figure 3a, 3b) and 7 with partial
remission (Figure 4a, 4b) (1 had complete remission of rectal
varices). No patients in any group died within 12 months
after surgery (Table 2).
Table 3 presents associations between postoperative
bleeding and other factors. No associations were found
between the included factors (all p-value40.05) (Table 3).
’ DISCUSSION
The results of this retrospective pilot study showed that
the safety and efficacy of shunt surgery combined with foam
sclerotherapy were comparable to the safety and efficacy
of shunt surgery plus devascularization for patients with
PPH. Notably, both shunt surgery plus foam sclerotherapy
and shunt surgery plus devascularization were superior to
shunt surgery alone in terms of preventing recurrence and
rebleeding.
The goal of PPH treatment is the control and prevention
of gastrointestinal bleeding. Unlike in patients with hepatic
cirrhosis-related portal hypertension, gastroesophageal varices
in PPH are evidently causing more blood loss, and con-
comitant esophageal and gastric varices are more common
(31%-44% vs. 22%). Some PPH patients have concomitant
rectal and anal varices. Isolated varicose veins are found in
approximately 6% of PPH patients, and ectopic or duodenal
varices are also common (17,18).
Surgery is the conventional treatment of choice for PPH
according to the guidelines of the American Association for
the Study of Liver Diseases (19), but with the development of
minimally invasive treatment, endoscopy and interventional
procedures have become the preferred treatments. Evidence
shows that the efficacy of hemostasis by endoscopy is as high
as 90% in the emergency department (4), and endoscopy is
especially applicable in patients with acute bleeding who are
not candidates for open surgery. Endoscopy is also employed
to prevent bleeding, but it cannot reduce portal pressure and
Table 2 - Comparisons of intraoperative and postoperative characteristics (n=27).
Total (n=27) Group A (n=10) Group B (n=8) Group C (n=9) p-value
Characteristics during surgery
Operation time (min) 243.0±64.5 241.0±92.0 246.2±31.7 242.2±55.7 0.986
Intraoperative blood loss (ml) 653.7±683.7 925.0±962.4 475.0±315.1 511.1±493.6 0.613
Preshunting portal pressure level (cm H2O) 42.4±6.8 46.1±6.7 40±7.9 40.3±4.1 0.085
Postshunting portal pressure level (cm H2O) 32.3±5.3 35.2±5.3 30.7±5.0 30.5±4.8 0.099
Reduction level of portal pressure (cm H2O) 10.1±5.0 10.9±6.7 9.2±4.6 9.8±3.4 0.931
Within 30 days after surgery
Complications 6 (22.2) 2 (20) 2 (25) 2 (22.2) 1.000
30-days mortality 0 (0) 0 (0) 0 (0) 0 (0) NA
Within 12 months after surgery
Recurrent bleeding 3 (11.1) 2 (20) 1 (12.5) 0 (0) 0.614
Encephalopathy 2 (7.4) 1 (10) 0 (0) 1 (11) NA
Shunt occlusion 1 (3.7) 1 (10) 0 (0) 0 (0) NA
Remission level of varices o0.001*
Completed remission 2 (7.4) 0 (0) 0 (0) 2 (22.2)
Partial remission 14 (51.9) 1 (10) 6 (75) 7 (77.8)
No remission 11 (40.7) 9 (90) 2 (25) 0 (0)
Remission rate 16 (59.3) 1 (10) 6 (75) 9 (100) o0.001*
Mortality rate 0 (0) 0 (0) 0 (0) 0 (0) NA
Data are summarized as the mean±SD for continuous data and as n(%) for categorical data. Differences among groups were compared using the Kruskal-
Wallis test for continuous data and Fisher’s exact test for categorical data.
*po0.05, indicates significant differences between groups.
NA, not available.
Three patients exhibited recurrent bleeding at 4 months, 10 months, and 10.5 months after the operation.
5
CLINICS 2019;74:e704 Treatments for prehepatic portal hypertension
Zhang Z et al.
may increase the risk for recurrent gastric varices and ectopic
varices (20). Bleeding recurrence is common after endoscopy,
with a rate as high as 40%-70% (21,22). Therefore, regular
follow-up and repeated treatments are needed for patients
who receive endoscopy alone, but this therapeutic pattern is
often inapplicable in developing countries. Interventional
procedures such as TIPS and percutaneous mesocaval shunt
creation are minimally invasive and suitable for patients who
cannot undergo open surgery, although portal vein obstruc-
tion or chronic portal vein thrombosis remains a relative
contraindication to TIPS (11,23). Additionally, the technique
for percutaneous mesocaval shunt placement is a challenging
and potentially precarious procedural approach requiring
transmesenteric, intraperitoneal vessel puncture and clinical
experience is limited. PPH may also cause other complica-
tions, such as splenomegaly, hypersplenism, growth and
development disorders, portal hypertensive gastropathy and
ectopic varices, which cannot be managed by endoscopy.
Thus, treatment must be individualized, and comprehensive
treatment is required for PPH patients.
To date, surgery remains an effective treatment for PPH,
and the long-term survival rate of PPH is higher than 95%
after shunt surgery (24). Its morbidity and mortality can be
minimized by experienced surgeons. However, few studies
have compared the efficacy between shunt surgery and
endoscopy. A single-center, randomized, controlled study
indicated that the mortality was comparable between shunt
surgery and endoscopy in PPH patients, but the rate of
bleeding recurrence in the endoscopy group (22.6%) was
significantly higher than that in the shunt surgery group
(3.3%), and a high rate of treatment failure was also found in
the endoscopy group (19.4% vs. 6.7%) (25). Surgery is also
reported to improve pediatric patients’ growth and devel-
opment, attenuate the development of varices, and relieve
PPH-related biliary diseases (26,27). Accepted indications for
surgery for PPH include (1) acute gastrointestinal bleeding
that is nonresponsive to endoscopic hemostasis; (2) gastric
and ectopic varicose veins for which endoscopic treatment is
too difficult to perform; (3) the presence of splenomegaly,
hypersplenism, growth and development disorders, portal
hypertensive biliary tract disease or other diseases; and (4)
when patients have difficulty making repeat hospital visits
and are willing to receive one-time treatment (12).
In the present study, all patients had portal obstruction, so
the mesocaval shunt technique was employed. The blood
flow shunted is less than that with the portocaval shunt,
reducing the risk for postoperative hepatic encephalopathy.
Because the long distance between the superior mesenteric
vein and inferior vena cava may make direct anastomosis
difficult, an artificial (prosthetic) vessel can be used for the
shunt between these vessels. However, artificial vessels have
a low long-term patency rate and cannot grow over time;
thus, the use of a prosthetic is inapplicable in children. For
patients with severe splenomegaly or hypersplenism, shunt
surgery should be prepared during splenectomy, and a
proximal splenorenal shunt is preferred for surgical inter-
vention. Splenectomy cannot effectively reduce the portal
pressure or relieve esophageal and gastric varicosities but
can increase the susceptibility to splenic vein thrombosis,
which may risk involvement of the portal vein and superior
mesenteric vein. This condition requires performing shunt
surgery (28), and splenectomy alone should be avoided for
these patients.
Although shunt surgery effectively reduces portal pres-
sure, recurrent bleeding is still possible after surgery due to
obstruction of shunt vessels and/or residual varicose veins
(29). PPH patients may have large varicose veins, and even
though pressure is reduced, the dilated vessels cannot
remodel, and thin-walled veins may rupture. In the present
study, although the absence of varices was not associated
with postoperative recurrence of bleeding, three patients
with recurrent bleeding had no improvement in varices after
surgery, indicating that residual varicose veins may increase
the risk for bleeding recurrence. Therefore, in shunt surgery,
eliminating varices is necessary for concomitant devascular-
ization or concomitant foam sclerotherapy.
Theoretically, the combined use of shunt and devascular-
ization not only reduces portal pressure but also removes
residual varicose veins, helping to prevent recurrent bleeding.
Feng et al. (30) achieved favorable efficacy using mesocaval
artificial vessel shunts, ligation of gastric fundal veins and
coronary veins of the stomach, and partial splenectomy. In that
study of 100 patients, no recurrence, bleeding or hepatic
encephalopathy were observed during follow-up. In the
present study, among the eight patients (Group B) who
underwent surgical intervention with shunt creation and
Figure 3 - Perioperative enhanced CT images. a) Gastroesophageal varices on preoperative enhanced CT. b) Absence of varicose veins on
postoperative enhanced CT after foam sclerotherapy in the same patient.
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devascularization and received a postoperative CT scan,
six patients had remission of varices, indicating that the
combined use of a shunt and devascularization is effective
for attenuating varices. However, two patients still had no
attenuation of varices, which might be ascribed to residual
varicose veins due to incomplete devascularization. In
addition, devascularization sometimes requires expansion
of the surgical field to expose the varicose veins completely,
which may increase surgical risk and difficulty compared
to shunt surgery alone. Therefore, we attempted to combine
a shunt with foam sclerotherapy to replace conventional
shunt surgery, aiming to effectively remove the varicose
veins and simplify the surgery.
Foam sclerotherapy has been widely used in treating limb
varices, endoscopic sclerotherapy and balloon-occluded
retrograde transvenous obliteration (BRTO), and can effec-
tively close varicose veins. However, direct injection of
sclerosant into fundal varicose veins during open surgery
Figure 4 - Endoscopy images. a) Preoperative endoscopy showing gastroesophageal varices. b) Endoscopy review of the same patient
showing obviously decreased gastric varices but residual esophageal varices postoperatively.
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has not been reported. Based on the classification of gastric
varices, some patients have both esophageal and gastric
varices with connections between the varicose veins (GOV1
type and GOV2 type) (31). After injecting sclerosant into
fundal varicose veins, it may be distributed to the entire
varices system via communicating collaterals and even
further up to the esophageal veins. One-time injection may
cause the obstruction of a wide range varices, which increases
the efficacy of varicose vein removal and decreases surgical
trauma and difficulty. In addition, ectopic varicose veins
(e.g., rectal veins) that are difficult to expose anatomically
can also be managed with hybrid surgery. The catheter can
be inserted into the distal lesion with the aid of digital
subtraction angiography (DSA), and the sclerosant is then
injected to obstruct the varicose veins, which may also
simplify this complex surgery.
In the present study, we used polidocanol, a liquid
embolizing agent of the sclerosing class, as the foam sclerotic
reagent and found it to be safe and effective. This reagent
has been widely used in the treatment of limb varicosis and
venous malformation, as well as in endoscopic treatment
(32,33). Polidocanol is mixed with gas (1:4) to form the foam
sclerotic reagent. This reagent can damage vascular endothe-
lial cells chemically, leading to thrombosis, fibrosis and final
permanent occlusion. Foam sclerosant has several advan-
tages over liquid sclerosant: a lower dose of foam sclerosant
can be used, increasing safety, and the distribution of foam
sclerosant is even greater in the vessels, increasing the area of
sclerosant contacting vessel walls and elevating the efficacy
of sclerotherapy (34). Darke et al. (35) reported that poli-
docanol foam effectively induced occlusion of varicose
veins of the lower limbs with 490% overall effectiveness.
The results of a multicenter study showed that the efficacy
of foam sclerotherapy (69%) was significantly higher than
that of liquid sclerotherapy (27%) in patients with lower
extremity varices (36). Foam sclerosant is also used in
BRTO. Several studies employed retrograde injection of
polidocanol foam via a spontaneous gastrorenal shunt to
obstruct fundal varicose veins, resulting in an obstruction
rate as high as 91%-100%, and only one patient had bleed-
ing recurrence during follow up (37-39).
Foam sclerotherapy is usually performed after shunt
surgery because the shunt reduces the pressure of the
esophageal and fundal veins and decreases the blood flow
from the varicose veins into systemic circulation. Therefore,
injection of foam sclerosant after shunt surgery may not
induce systemic embolism. In shunt surgery, the varicose
veins at the greater curvature, lesser curvature and fundus
are completely exposed, and 2-5 ml of polidocanol foam is
then injected into the target vessels. Before injection, with-
drawal of the syringe is needed to ensure that the needle
localizes in the vessel lumen. Stable injection may be difficult
when the target vessels are small or curled or if the space is
narrow. In such cases, an intravenous infusion needle with
extended tubes can be used to inject the foam sclerosant,
increasing needle stability. The sclerosant dose should be
determined based on the severity of varices before and
during surgery. The sclerosant dose can usually reference
that used in the treatment of limb varices, in which 2-5 ml
of sclerosant is injected into each vessel, and the dose can be
increased for larger varicose veins. Polidocanol is available
in concentrations of 0.5%, 1% and 3%; 1% polidocanol is
most commonly used in treating fundal varices, while 3%
polidocanol is used if the diameter of varicose veins is larger
than 6 mm. For fundal varices, pressurization is inapplicable
after injection of foam sclerosant, and unsuccessful obstruc-
tion of the target vessels may increase the possibility of
recirculation. Studies with long follow-up are needed to
determine whether this will affect long-term efficacy.
In the present study, although none of the patients in
Group C who received shunt + foam sclerotherapy had
rebleeding, 20% of patients receiving shunt surgery alone
(Group A) and 12.5% of patients receiving shunt surgery+
devascularization (Group B) developed rebleeding within
12 months after surgery. For short-term efficacy, shunt surgery
combined with foam sclerotherapy prevented postopera-
tive recurrent bleeding more effectively, although signifi-
cant differences were not observed among the three groups,
so we cannot conclude that the new approach is superior to
the conventional one. Further comparisons of findings from
abdominal enhanced CT or gastroscopy before and after
surgery showed decreased varices in more patients in
Groups B and C than in Group A due to the treatment of
fundal varicose veins in addition to shunt surgery in
Groups B and C. Postoperative imaging in Group C showed
that the esophageal and gastric varices decreased in all
patients within 12 months, with complete remission in two
patients and partial remission in seven patients, suggesting
that obstruction of varicose veins with foam sclerosant has
favorable efficacy. Notably, complete remission was not
achieved in seven patients due to residual esophageal
varices, which might be ascribed to the large vascular
volume and the insufficient amount of sclerosant applied.
Injection of foam sclerosant into the fundal veins alone
may not spread into esophageal veins, but a decrease in
fundal varices theoretically improves the prognosis of PPH
Table 3 - Associations between postoperative bleeding and clinical factors.
With postoperative bleeding (n=3a) Without postoperative bleeding (n=24) p-value
Operation time (min) 240±80 243.3±64.4 0.856
Intraoperative blood loss (ml) 750±1082.8 641.7±652.0 0.532
Reduction level of portal pressure (cm H2O) 7.7±0.6 10.4±5.3 0.532
Etiology
Portal cavernoma 2 (66.7) 14 (58.3) 1.000
Chronic portal vein thrombosis 1 (33.3) 10 (41.7) 1.000
Encephalopathy 1 (33.3) 1 (4.2) 0.214
Complications 1 (33.3) 5 (20.8) 0.545
Remission rate within 12 months after operation 0 (0) 16 (66.7) 0.056
a Two patients in Group A and one patient in Group B had rebleeding within 12 months after operation.
Data are presented as n(%) and were analyzed using Mann-Whitney test for continuous data or Fishers’ exact test for categorical data.
No significant associations were derived.
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patients. When the pressure gradient between the portal
and systemic vein is o12 mmHg after shunt or TIPS
placement, recurrent bleeding due to esophageal varices is
rare, but fundal varices may still cause repeated bleeding
(40). In addition, residual esophageal varices can also be
managed by endoscopy, but the efficacy of endoscopy for
fundal varices is inferior to that for esophageal varices (41).
Therefore, a decrease in fundal varices after foam scler-
otherapy is crucial for the control of postoperative recurrent
bleeding.
Foam sclerotherapy is simpler to perform than devascu-
larization. Although no significant differences were found in
operation time or intraoperative blood loss in our patients
who received foam sclerotherapy, this technique only
requires exposure of fundal varicose veins and subsequent
injection of sclerosant without excessive exposure of the
surgical field. The hybrid surgery we used employs both
interventional procedures and foam sclerotherapy, which can
resolve difficulties common in conventional surgery (such as
ectopic or rectal varices) with minimal invasion. In rectal and
anal varices, redistribution of the portal vein may cause
increased pressure in the inferior mesenteric vein. Although
the rate of relevant bleeding is low (0.5%-10%), severe or
even life-threatening consequences may still develop (42,43).
One patient in Group C who had concomitant rectal varices
had a history of repeated bloody stool and severe anemia
before surgery. This lesion was hard to treat by conventional
surgery, and rectal resection might be needed. In the shunt
surgery, hybrid surgery was employed and involved catheter
insertion via the inferior mesenteric vein and injection of
sclerosant to obstruct the rectal varices. After the hybrid
procedure, the rectal varices were occluded, and the bloody
stool was relieved.
Typically, PPH patients have normal liver function or mild
liver dysfunction, and the prognosis is good after surgery. In
the present study, all patients had Child-Pugh class A or B
cirrhosis and were tolerant of surgery with low surgical risk
compared to those with decompensated liver function. In
addition, no significant differences were found in 30-day
postoperative mortality, operation times or intraoperative
blood loss among the three groups, indicating similar safety
between the different procedures. In one patient in Group C
who developed upper gastrointestinal bleeding, endoscopy
showed ulcer formation rather than ruptured varices after
endoscopic glue obturation. Other studies have reported
severe complications due to the shedding of tissue glue after
endoscopic therapy (44,45). During the 12-month follow-up,
all patients in the present study survived. Although hepatic
encephalopathy was noted in one patient in Group A and
one patient in Group C, it did not progress to hepatic coma
and resolved after conservative treatment.
Compared with other sclerosants, such as sodium tetra-
decyl sulfate, polidocanol foam is reported to be more stable
and has fewer side effects (45). The manufacturer’s instruc-
tions advise a maximal safe dose of 2 mg/kg/d, suggesting
that polidocanol at o2 mg/kg/d is safe. Evaluation of the
safety and efficacy of polidocanol in 16804 patients who
received sclerotherapy showed no allergy or death, indicat-
ing favorable safety (47). However, excessive amounts of
polidocanol has been administered without sclerotherapy-
related complications (48,49). Studies also indicate that foam
sclerosant in the blood may not cause biological reactions,
except for a transient increase in D-dimer (50). Although
complications such as cardiac toxicity and pulmonary
embolism do arise, the incidence is low (51), and lower
doses of sclerosant are better than giving the maximal dose.
In the present study, nine patients received 8-25 ml of 1%
polidocanol (median: 16.9 ml). Given a liquid to air ratio
of 1:4, the actual dose of polidocanol used was 16-50 mg.
Rectal varices were treated in one patient with 10 ml of 3%
polidocanol, which was equivalent to 60 mg of polidocanol
and was lower than the maximal dose, and no sclerosant-
related complications were observed, corroborating the safety
of treating varices with polidocanol foam sclerosant.
Limitations
The present pilot study still has several limitations. The
incidence of PPH was low, leading to a small sample size.
Because conducting a single-center, prospective, randomized
controlled study of a new approach is difficult, the new
approach can only be compared retrospectively to the conven-
tional one. Additionally, only short-term efficacy was evaluated,
and it is not clear whether risk exists for long-term vascular
recanalization after foam sclerotherapy and whether significant
differences may be found in long-term recurrent bleeding and
survival rates among the surgical groups. Although no
significant differences were found in patients’ baseline char-
acteristics (etiology, gender, age, complications and liver
function), study bias may still exist, emphasizing the need
for more multicenter, prospective, randomized controlled
studies to confirm the results of the current trial.
’ CONCLUSION
Shunt surgery combined with foam sclerotherapy has
similar safety and efficacy as shunt surgery with devascular-
ization. This combined procedure provides more effective
variceal obliteration than shunt surgery alone does, and the
combined procedure may reduce the risk of postoperative
recurrent bleeding caused by residual gastroesophageal varices.
In addition, foam sclerotherapy is easy to perform, is safe and
has favorable short-term efficacy in combination with shunt
surgery, but its long-term efficacy requires further study.
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